8 patents
Utility
Compositions and Methods for Regulating Immune System Activity
25 May 23
A trigger-responsive immune-inactivating signaling polypeptide disclosed herein can include a modulating domain and an immune-inactivating moiety, such as a dominant negative signaling moiety or constitutively active signaling moiety.
Peter J. Kushner, Leslie Hodges Gallagher, Cyrus L. Harmon, David C. Myles, Richard Sun
Filed: 23 Feb 18
Utility
Methods of Treating Estrogen Receptor-associated Diseases
27 Apr 23
The present disclosure provides methods of treating estrogen receptor-associated diseases, disorders, and conditions.
Cyrus L. Harmon, Peter J. Kushner, David C. Myles, Leslie Hodges Gallagher
Filed: 5 Mar 21
Utility
RepublicationRegimens of Estrogen Receptor Antagonists
6 Apr 23
Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer.
Cyrus L. Harmon, Peter J. Kushner, David C. Myles, Leslie Hodges Gallagher, Richard Sun
Filed: 6 Jul 20
Utility
TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
24 Nov 22
The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
David C. Myles, Peter J. Kushner, Cyrus L. Harmon
Filed: 6 Dec 21
Utility
Regimens of Estrogen Receptor Antagonists
25 Aug 22
Provided herein are methods of administering estrogen receptor antagonists for use in treatment of cancer.
Cyrus L. Harmon, Peter J. Kushner, David C. Myles, Leslie Hodges Gallagher, Richard Sun
Filed: 6 Jul 20
Utility
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
25 Jan 22
The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
David C. Myles, Peter J. Kushner, Cyrus L. Harmon
Filed: 17 Apr 20
Utility
TETRAHYDRO-1H-PYRIDO [3,4-b]INDOLE ANTI-ESTROGENIC DRUGS
4 Mar 21
The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
David C. Myles, Peter J. Kushner, Cyrus L. Harmon
Filed: 17 Apr 20
Utility
Tetrahydro-1H-pyrido [3,4-b]indole anti-estrogenic drugs
20 Apr 20
The present disclosure provides tetrahydro-1H-pyrido[3,4-b]indole compounds or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, stereoisomer, tautomer, rotamer, N-oxide and/or substituted derivative or, optionally in a pharmaceutical composition, for the modulation of disorders mediated by estrogen, or other disorders as more fully described herein.
David C. Myles, Peter J. Kushner, Cyrus L. Harmon
Filed: 22 Apr 19
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first